Home /
Treatment Details – 9.4 months
|
|
Description: |
Patients: This Phase II trial involved 32 patients with malignant pleural mesothelioma. None of these patients had received prior chemotherapy.
Treatment: The treatment consisted of two chemotherapy drugs, gemcitabine (gemzar) and cisplatin (platinol). Toxicity: Grade 4 toxicities included nausea and vomiting. Grade 3 toxicities included hematologic, nausea and vomiting, fatigue anorexia, diarrhea, neurotoxicity, cardiovascular. Results: The median survival from the start of treatment was 9.4 months. Support: This study was supported in part by Lilly BV. Lilly markets gemzar. Correspondence: JP van Meerbeeck, MD |